BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18516204)

  • 1. Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.
    Chan DC; Barrett PH; Watts GF
    Clin Biochem Rev; 2004 Feb; 25(1):31-48. PubMed ID: 18516204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods.
    Chan DC; Barrett PH; Watts GF
    Clin Sci (Lond); 2004 Sep; 107(3):233-49. PubMed ID: 15225143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies.
    Watts GF; Chan DC; Ooi EM; Nestel PJ; Beilin LJ; Barrett PH
    Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):877-82. PubMed ID: 16922825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
    Chan DC; Barrett PH; Watts GF
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological regulation of dyslipoproteinaemia in insulin resistant states.
    Chan DC; Watts GF
    Curr Vasc Pharmacol; 2008 Jan; 6(1):67-77. PubMed ID: 18220942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
    Watts GF; Ooi EM; Chan DC
    Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders.
    Chan DC; Barrett PH; Watts GF
    Curr Opin Lipidol; 2006 Feb; 17(1):28-36. PubMed ID: 16407713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.
    Chan DC; Barrett PH; Watts GF
    Clin Sci (Lond); 2004 Sep; 107(3):221-32. PubMed ID: 15225121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
    Chan DC; Barrett HP; Watts GF
    Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling lipoprotein metabolism with stable isotopes: tracing the flow.
    Ying Q; Chan DC; Barrett PHR; Watts GF
    Metabolism; 2021 Nov; 124():154887. PubMed ID: 34508741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
    Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
    J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism.
    Chan DC; Barrett PH; Watts GF
    Curr Opin Lipidol; 2016 Dec; 27(6):550-556. PubMed ID: 27749370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between skeletal muscle fat content and very-low-density lipoprotein-apolipoprotein B-100 transport in obesity: effect of weight loss.
    Chan DC; Gan SK; Wong AT; Barrett PH; Watts GF
    Diabetes Obes Metab; 2014 Oct; 16(10):994-1000. PubMed ID: 24821431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.
    Kwiterovich PO
    Am J Cardiol; 2002 Oct; 90(8A):30i-47i. PubMed ID: 12419479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.